Skip to main content
. 2023 Dec 20;11:1279656. doi: 10.3389/fpubh.2023.1279656

Table 3.

Serotypes of the isolates responsible for non-invasive pneumococcal pneumonia in adult patients (≥18 years) in Portugal, 2012–2018.

Serotypea No of isolates (%) CA 16–18b CA 12–18b
Current study period
2012 2013 2014 2015 2016 2017 2018
PCV13
3 48 (13.0) 54 (16.9) 41 (13.4) 53 (12.5) 52 (13.4) 56 (14.4) 60 (16.2) 0.275 0.610
4 1 (0.3) 1 (0.3) 2 (0.7) 3 (0.7) 0 (0.0) 0 (0.0) 1 (0.3) 0.211 0.400
6A 5 (1.4) 7 (2.2) 6 (2.0) 9 (2.1) 5 (1.3) 3 (0.8) 1 (0.3) 0.112 0.041
6B 7 (1.9) 4 (1.3) 4 (1.3) 6 (1.4) 3 (0.8) 3 (0.8) 3 (0.8) 0.954 0.102
7F 5 (1.4) 4 (1.3) 4 (1.3) 5 (1.2) 0 (0.0) 1 (0.3) 2 (0.5) 0.146 0.021
9V 0 (0.0) 5 (1.6) 0 (0.0) 0 (0.0) 1 (0.3) 1 (0.3) 1 (0.3) 0.973 0.400
14 12 (3.3) 6 (1.9) 6 (2.0) 10 (2.4) 13 (3.3) 8 (2.1) 7 (1.9) 0.191 0.534
18C 4 (1.1) 1 (0.3) 1 (0.3) 1 (0.2) 3 (0.8) 4 (1.0) 1 (0.3) 0.413 0.759
19A 17 (4.6) 9 (2.8) 18 (5.9) 14 (3.3) 10 (2.6) 11 (2.8) 11 (3.0) 0.741 0.104
19F 22 (6.0) 22 (6.9) 15 (4.9) 26 (6.1) 26 (6.7) 16 (4.1) 28 (7.5) 0.639 0.903
23F 4 (1.1) 2 (0.6) 4 (1.3) 2 (0.5) 4 (1.0) 2 (0.5) 2 (0.5) 0.413 0.378
addPCV15
22F 14 (3.8) 8 (2.5) 6 (2.0) 21 (5.0) 15 (3.9) 11 (2.8) 13 (3.5) 0.781 0.827
33F 6 (1.6) 1 (0.3) 7 (2.3) 3 (0.7) 5 (1.3) 4 (1.0) 3 (0.8) 0.518 0.474
addPCV20
11A 29 (7.9) 29 (9.1) 22 (7.2) 40 (9.5) 34 (8.7) 28 (7.2) 40 (10.8) 0.332 0.421
8 7 (1.9) 10 (3.1) 6 (2.0) 16 (3.8) 11 (2.8) 16 (4.1) 16 (4.3) 0.278 0.039
15B/C 6 (1.6) 11 (3.4) 7 (2.3) 10 (2.4) 7 (1.8) 16 (4.1) 13 (3.5) 0.172 0.134
10A 11 (3.0) 6 (1.9) 5 (1.6) 10 (2.4) 13 (3.3) 13 (3.3) 8 (2.2) 0.339 0.661
addPPV23
9N 11 (3.0) 13 (4.1) 16 (5.2) 12 (2.8) 20 (5.1) 23 (5.9) 17 (4.6) 0.737 0.122
20 5 (1.4) 5 (1.6) 6 (2.0) 8 (1.9) 9 (2.3) 4 (1.0) 6 (1.6) 0.442 0.994
17F 8 (2.2) 4 (1.3) 8 (2.6) 4 (0.9) 4 (1.0) 6 (1.5) 7 (1.9) 0.314 0.595
NVT
23B 15 (4.1) 8 (2.5) 15 (4.9) 18 (4.3) 16 (4.1) 20 (5.1) 26 (7.0) 0.078 0.025
23A 24 (6.5) 12 (3.8) 14 (4.6) 17 (4.0) 27 (6.9) 19 (4.9) 16 (4.3) 0.107 0.692
29/35B 12 (3.3) 6 (1.9) 6 (2.0) 10 (2.4) 9 (2.3) 22 (5.7) 12 (3.2) 0.483 0.104
6C 19 (5.2) 16 (5.0) 7 (2.3) 22 (5.2) 11 (2.8) 13 (3.3) 15 (4.0) 0.356 0.238
15A 10 (2.7) 9 (2.8) 8 (2.6) 16 (3.8) 15 (3.9) 15 (3.9) 8 (2.2) 0.194 0.749
35F 5 (1.4) 3 (0.9) 6 (2.0) 14 (3.3) 18 (4.6) 9 (2.3) 4 (1.1) 0.002 0.301
31 15 (4.1) 7 (2.2) 14 (4.6) 12 (2.8) 6 (1.5) 14 (3.6) 9 (2.4) 0.424 0.269
16F 7 (1.9) 10 (3.1) 3 (1.0) 20 (4.7) 12 (3.1) 12 (3.1) 1 (0.3) 0.008 0.491
NT 9 (2.4) 8 (2.5) 10 (3.3) 3 (0.7) 8 (2.1) 7 (1.8) 9 (2.4) 0.727 0.538
21 3 (0.8) 6 (1.9) 7 (2.3) 8 (1.9) 11 (2.8) 5 (1.3) 4 (1.1) 0.064 0.939
34 3 (0.8) 8 (2.5) 5 (1.6) 8 (1.9) 7 (1.8) 4 (1.0) 4 (1.1) 0.377 0.596
37 1 (0.3) 4 (1.3) 1 (0.3) 3 (0.7) 4 (1.0) 6 (1.5) 2 (0.5) 0.518 0.373
24F 4 (1.1) 2 (0.6) 6 (2.0) 10 (2.4) 0 (0.0) 5 (1.3) 5 (1.3) 0.044 0.993
25A/38 7 (1.9) 2 (0.6) 0 (0.0) 0 (0.0) 1 (0.3) 1 (0.3) 3 (0.8) 0.252 0.118
13 2 (0.5) 3 (0.9) 1 (0.3) 1 (0.2) 2 (0.5) 1 (0.3) 2 (0.5) 0.966 0.552
7C 2 (0.5) 2 (0.6) 6 (2.0) 1 (0.2) 2 (0.5) 0 (0.0) 2 (0.5) 0.969 0.223
6D 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.8) 0 (0.0) 0.973 0.096
35A 2 (0.5) 3 (0.9) 4 (1.3) 2 (0.5) 1 (0.3) 0 (0.0) 2 (0.5) 0.457 0.167
Other 6 (1.6) 8 (2.5) 8 (2.6) 5 (1.2) 4 (1.0) 7 (1.8) 7 (1.9) -

aOnly serotypes detected in ≥3 isolates in at least 1 year are shown. The remaining serotypes are included in “Other” and include serotypes 18A, 1, 12B, 10B, 47F, 11F, 17A, 10F, 12F, 36, 11B, 7B, 11D, 35C, 18F, 42, 11C, 28A and 19B. PCV13, serotypes included in PCV13; addPCV15, the additional serotypes included in PCV15 which are not present in PCV13; addPCV20, the additional serotypes included in PCV20 which are not present in PCV15; addPPV23, the serotypes exclusively found in PPV23; NVT, non-vaccine serotypes. bCA, Cochran Armitage test for trend for each of the indicated periods: 2016–2018 and 2012–2018. Values < 0.05 are indicated in bold.